*nlm.life
			PubMed Journals: Biochem Biophys Res Commun

  Source:		PMID: 15607755
  Download:	https://www.sciencedirect.com/science/article/pii/S0006291X04027299

    		Biochem Biophys Res Commun. 2005 Jan
     		28;326(4):905-8.

			Ribavirin and interferon-beta synergistically
			inhibit SARS-associated coronavirus replication in
			animal and human cell lines.

			Morgenstern B(1), Michaelis M, Baer PC,
			Doerr HW, Cinatl J Jr.

			Author Information
			(1) Institute of Medical Virology, Johann
			Wolfgang Goethe University Frankfurt,
			Paul-Ehrlich-Str. 40, 60596 Frankfurt, Germany.

			Initial in vitro investigations demonstrated
			type I interferons (IFNs: IFN-alpha, IFN-beta)
			to inhibit replication of SARS coronavirus
			(SARS-CoV), but found the nucleoside analogue
			ribavirin ineffective in Vero cells. In
			this report, ribavirin was shown to inhibit
			SARS-CoV replication in five different cell
			types of animal or human origin at therapeutically
			achievable concentrations. Since clinical
			anti-SARS-CoV activity of type I interferons
			or ribavirin is limited, we investigated
			the combination of IFN-beta and ribavirin.
			Determination of the virus yield indicated highly
			synergistic anti-SARS-CoV action of the
			combination suggesting the consideration
			of ribavirin plus IFN-beta for the treatment
			of SARS.

			DOI: 10.1016/j.bbrc.2004.11.128 PMID: 15607755
			[Indexed for MEDLINE]

     			                         Tweet       Print